ex.VAT:
VAT:
inc.VAT:

Tuesday, July 7, 2020News

Oxilata from Biocosmethic: the Chinese orchid that preserves the skin's youthfulness

Oxilata de Biocosmethic : l'orchidée chinoise qui préserve le capital jeunesse de la peau

Inspired by traditional Chinese medicine, Oxilata is a new approach in the field of anti-aging. Its action on the endothelial cells that protects the microcirculation offers a global and natural solution to fight against premature ageing, preserve the skin’s architecture and maintain its youthfulness through deep detoxification.

Reading time
~ 2 minutes

Also known as Tianma (plant of the sky) or Shencao (divine herb) in Chinese, Gastrodia elata is a Chinese divine orchid that is distinguished by a complete mycoheterotrophic lifestyle. Endophytes give it unique medicinal values that improve health, rejuvenate the body and prolong life. This orchid has been used for thousands of years in traditional Chinese medicine for its powerful detoxifying effect and eliminating external and internal causes of disease.

Mode of action

Extracted from the root of Gastrodia elata, obtained by a green process, Oxilata is a 100% natural, preservative-free ingredient, particularly rich in polysaccharides and COSMOS approved.
It acts on :
• Oxidative stress: elimination of excess ROS (on keratinocytes and microvascular endothelial cells)
• Skin microcirculation: skin detoxification (on microvascular endothelial cells)
• Photoaging: protection of skin proteins and preservation of skin architecture (ex vivo)
• Premature aging: elimination of excess progerin (on fibroblasts)
• Inflammaging: elimination of excess pro-inflammatory cytokines (on keratinocytes and microvascular endothelial cells)
In vivo versus placebo, Oxilata 1% in a standard O/W emulsion significantly induces not only a smoothing and anti-wrinkle effect but also relieves bags under the eyes after only 28 days of treatment.

Consumer benefits

Oxilata can …

This content is only available to subscribersPREMIUM, PRO, STARTUP and TPE

Already subscribed?Log in

Discover our subscriptions

NewsOther articles